Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings suggest that the inflammatory milieu in the epidermal microenvironment in psoriasis is more likely dependent on evolutionarily ancient cytokines such as IL-1, rather than those of the adaptive immune response.
|
17591951 |
2007 |
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
To determine what role the IL-1 system might contribute to the inflammatory process in psoriasis, semi-quantitative RT-PCR and cRNA microarray studies were performed on biopsies excised from lesional and non-lesional skin.
|
16460958 |
2006 |
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The IL-1 gene complex may play a role in the development of PsA and/or psoriasis or act as a marker for other genes on chromosome 2q12 to 2q13.
|
12890860 |
2004 |
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
There are over 300,000 patients worldwide being treated with agents that specifically block the biological activities of interleukin-1 (IL-1) or tumor necrosis factor (TNF) for reducing the severity of autoimmune diseases such as rheumatoid arthritis, Crohn's disease or psoriasis.
|
12763679 |
2003 |
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset.
|
11851889 |
2002 |
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We propose that activation of MAPK by integrins, either directly or through increased IL-1alpha production, is responsible for epidermal hyperproliferation in psoriasis and wound healing, and that the sporadic phenotype of the transgenic mice may reflect the complex mechanisms by which IL-1 release and responsiveness are controlled in skin.
|
11518726 |
2001 |
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
To thoroughly study the IL-1 system in psoriasis, we semiquantitatively analyzed the expression of all currently characterized IL-1 isoforms and their receptors in parallel in both lesional (PP) and nonlesional psoriatic (PN) epidermis.
|
9058835 |
1997 |
Psoriasis
|
0.400 |
Biomarker
|
disease |
CTD_human |
Increased mRNA expression of manganese superoxide dismutase in psoriasis skin lesions and in cultured human keratinocytes exposed to IL-1 beta and TNF-alpha.
|
7744320 |
1995 |
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Increased mRNA expression of manganese superoxide dismutase in psoriasis skin lesions and in cultured human keratinocytes exposed to IL-1 beta and TNF-alpha.
|
7744320 |
1995 |
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To better understand the cellular target(s) of cyclosporin action in psoriasis, we have studied the effects of systemic short-term (7 d), low-dose (3-7.5 mg/kg) cyclosporin A administration on the expression of the cytokines interleukin (IL)-8 and IL-1 beta in psoriatic lesions.
|
8245502 |
1993 |
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The profound and complex changes in this system suggest IL-1 dysregulation may be integrally involved in the inflammatory, biochemical, and proliferative processes involved in the pathophysiology of psoriasis.
|
2191038 |
1990 |
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using cryostat skin sections and an IL-1 beta-specific monoclonal antibody (MoAb) in an indirect immunoperoxidase technique, a diffuse staining in the entire epidermis was observed in sections of uninvolved skin from psoriasis patients.
|
2258628 |
1990 |